

Supernus Pharmaceuticals, Inc. Investor Relations Department 1550 East Gude Drive Rockville, MD 20850 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: SUPN	
Last Trade:	57.05
Trade Time:	4:00 PM ET Jun 22, 2018
Change:	-1.30 🖶 (-2.228%)
Day Range	55.65 - 58.85
52-Week Range	33.30 - 61.10
Volume	1,064,270

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... (more)

## **Stock Information**



## Press Releases [View all]

May 30, 2018

<u>Supernus to Present at the 2018 Jefferies</u> <u>Healthcare Conference</u>

May 8, 2018

Supernus Announces First Quarter 2018
Financial Results and Record Quarterly
Revenue

Apr 24, 2018

Supernus to Host First Quarter 2018
Earnings Conference Call

Mar 15. 2018

Supernus Announces Pricing of \$350 Million
Private Offering of 0.625% Convertible
Senior Notes

Mar 13, 2018

Supernus Announces Proposed Private
Offering of \$350 Million of Convertible Senior
Notes

## Financials & Filings [View all]

First Quarter Financial Results

Mar 1, 2018

Annual Report (10-K)

Apr 27, 2018

Proxy Statement (DEF 14A)

May 10, 2018

Quarterly Report (10-Q)

Nov 9, 2017

Quarterly Report (10-Q)

Aug 3, 2017

Quarterly Report (10-Q)